Subsequent chemotherapy with paclitaxel plus cetuximab-based chemotherapy following immune checkpoint inhibitor in recurrent or metastatic squamous cell carcinoma of the head and neck

Subsequent chemotherapy with paclitaxel plus cetuximab-based chemotherapy following immune checkpoint inhibitor in recurrent or metastatic squamous cell carcinoma of the head and neck

BackgroundImmune checkpoint inhibitors (ICIs) are essential in treating recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). However, the overall response rate (ORR) is limited to 10-20%, and subsequent chemotherapy is critical to maximizing the subjects’ prognosis.MethodsW...

Full description

Bibliographic Details
Main Authors: Hideki Tanaka, Tomohiro Enokida, Susumu Okano, Takao Fujisawa, Nobukazu Tanaka, Naohiro Takeshita, Ryutaro Onaga, Yuta Hoshi, Akihisa Wada, Masanobu Sato, Yuri Ueda, Makoto Tahara
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-11-01
Series:Frontiers in Oncology
Subjects:
pembrolizumab
subsequent chemotherapy
paclitaxel
cetuximab
carboplatin
recurrent/metastasis squamous cell carcinoma of the head and neck
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1221352/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1221352/full

Similar Items